Off-label use of rituximab in dermatology: Pemphigus treatment;Uso off-label do rituximab na dermatologia: Tratamento dos pênfigos

Anais Brasileiros de Dermatologia

Volumn 88, Issue 4, 2013, Pages 676-678

  Bomm, Lislaine ^a   Sodré, João Luz ^a   Fracaroli, Tainá Scalfoni ^a   Bressan, Aline ^a   Gripp, Alexandre Carlos ^a  

^a HOSPITAL UNIVERSITÁRIO PEDRO ERNESTO   (Brazil)

Author keywords

Biological treatment; Immunosuppressive agents; Pemphigus

Indexed keywords

AZATHIOPRINE; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DESMOGLEIN; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB;

ADULT; ANEMIA; ANGINA PECTORIS; ARTICLE; BRONCHOSPASM; CASE REPORT; CHILL; CYTOKINE RELEASE SYNDROME; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEMALE; FEVER; FOLLOW UP; HEPATITIS B; HUMAN; HYPOTENSION; INFECTION; INTESTINE OBSTRUCTION; LYMPHOCYTOPENIA; MALE; MUCOSAL DISEASE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OFF LABEL DRUG USE; PEMPHIGUS; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PLASMAPHERESIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; REMISSION; RHEUMATOID ARTHRITIS;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DERMATOLOGIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; OFF-LABEL USE; PEMPHIGUS; TREATMENT OUTCOME;

EID: 84884791471     PISSN: 03650596     EISSN: 18064841     Source Type: Journal    
DOI: 10.1590/abd1806-4841.20131905     Document Type: Article

References (7)

1. Carr DR, Heffernan MP. Off-label uses of rituximab in dermatology. Dermatol Ther. 2007;20:277-287.
2. Fatourechi MM, el-Azhary RA, Gibson L. Rituximab: applications in dermatology. Int J Dermatol. 2006;45:1143-1155.
3. Emer JJ, Wolinsky C. Rituximab: a review of dermatological applications. J Clin Aesthet Dermatol. 2009;2:29-37.
4. Cianchini G, Corona R, Frezzolini A, Ruffelli M, Didona B, Puddu P. Treatment of severe pemphigus with rituximab. Arch Dermatol. 2007;143:1033-1038.
5. Diab M, Galina K, Kurtz E. Treatment of refractory pemphigus erythematosus with rituximab. Int J Dermatol. 2008;47:1317-1318.
6. Allen KJ, Wolverton SE. The efficacy and safety of rituximab in refractory pemphigus: a review of case reports. J Drugs Dermatol. 2007;6: 883-889.
7. Müller R, Hunzelmann N, Baur V, Siebenhaar G, Wenzel E, Eming R, et al. Targeted immunotherapy with rituximab leads to a transient alteration of the IgG autoantibody profile in pemphigus vulgaris. Dermatol Res Pract. 2010;2010:321950. doi: 10.1155/2010/321950